Search - tctmd.com

Displaying 21 - 40 of 440

Sort: Relevancy | Date

Presentation TCT 2016

FORTITUDE: Nine-Month Clinical, Angiographic, and OCT Results With an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Antonio Colombo

October 31, 2016

Presentation TCT 2016

MeRes-1: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Ashok Seth

October 31, 2016

Presentation TCT 2016

FANTOM II: Six-Month and Nine-Month Clinical and Angiographic Results With a Radiopaque Desaminotyrosine Polycarbonate-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Alexandre Abizaid

October 31, 2016

News Industry News

First-In-Human Of New Polymer-Free Stent Demonstrates Favorable Angiographic And Imaging-Based Outcomes At Nine-Months

October 31, 2016

Presentation TCT 2016

TCT 29: Performance and Healing Patterns After Implantation of a Novel Sirolimus-Eluting Bioresorbable Scaffold. Six-Month Follow-Up by Optical Coherence Tomography in the FANTOM II Study

Presenter: Jacques J. Koolen, Yoshinobu Onuma, Jo Simonsen

October 31, 2016

Presentation TCT 2016

TCT 29: Performance and Healing Patterns After Implantation of a Novel Sirolimus-Eluting Bioresorbable Scaffold. Six-Month Follow-Up by Optical Coherence Tomography in the FANTOM II Study

Presenter: Jacques J. Koolen, Yoshinobu Onuma, Jo Simonsen

October 31, 2016

Presentation TCT 2016

REVELUTION: Nine-Month Clinical, Angiographic, IVUS, and OCT Outcomes With a Polymer-Free Sirolimus-Eluting Drug-Filled Stent

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Stephen G. Worthley

October 31, 2016

News Conference News TCT 2016

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Todd Neale

October 31, 2016

Presentation TCT 2016

TCT 317: Ten-Year Impact of Stent Fracture and Peri-Stent Contrast staining After Sirolimus-Eluting Stent Implantation on Target Lesion Revascularization

Presenter: Nicolas Foin, Giampaolo Niccoli

October 31, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Orsiro Cobalt Chromium Sirolimus-Eluting Stents

Presenter: Dean J. Kereiakes, Pieter C. Smits, Thomas Pilgrim

October 30, 2016

News Industry News

Very Thin-Strut Biodegradable Polymer Everolimus-Eluting And Sirolimus-Eluting Stents Shown To Be Non-Inferior To Durable Polymer Zotarolimus-Eluting Stents In All-Comers With Coronary Artery Disease

October 30, 2016

News Conference News TCT 2016

DES With Biodegradable Polymers Stand Up Well Against Durable-Polymer Stents in the Short Term

Todd Neale

October 30, 2016

News Daily News

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

Michael O'Riordan

October 18, 2016

News Daily News

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

Michael O'Riordan

October 18, 2016

News Daily News

A Tight Spot: Drug-Eluting Stents Seem to Top Other Options for Small-Vessel Disease

Todd Neale

June 16, 2016

News Industry News

STENTYS Announces CE Marking of its longest Xposition stent

June 08, 2016

News Daily News

Según un Meta Análisis en Red el Riesgo de Trombosis del Andamiaje con el BVS Absorb es Mayor que con Otros Stents

Michael O'Riordan

June 06, 2016

News Daily News

Higher Scaffold Thrombosis Risk With Absorb BVS vs a Wide Range of Stents: Network Meta-Analysis

Michael O'Riordan

June 06, 2016

News Industry News

iVascular completes recruitment of patients for its ANCHOR clinical trial of the sirolimus eluting stent ANGIOLITE

May 19, 2016

News Industry News

Micell Technologies Completes Enrollment in OCT Study Designed to Evaluate Superior Performance of MiStent SES Compared to Xience

March 22, 2016

Advertisement

FORTITUDE: Nine-Month Clinical, Angiographic, and OCT Results With an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

MeRes-1: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

FANTOM II: Six-Month and Nine-Month Clinical and Angiographic Results With a Radiopaque Desaminotyrosine Polycarbonate-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

First-In-Human Of New Polymer-Free Stent Demonstrates Favorable Angiographic And Imaging-Based Outcomes At Nine-Months

TCT 29: Performance and Healing Patterns After Implantation of a Novel Sirolimus-Eluting Bioresorbable Scaffold. Six-Month Follow-Up by Optical Coherence Tomography in the FANTOM II Study

TCT 29: Performance and Healing Patterns After Implantation of a Novel Sirolimus-Eluting Bioresorbable Scaffold. Six-Month Follow-Up by Optical Coherence Tomography in the FANTOM II Study

REVELUTION: Nine-Month Clinical, Angiographic, IVUS, and OCT Outcomes With a Polymer-Free Sirolimus-Eluting Drug-Filled Stent

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

TCT 317: Ten-Year Impact of Stent Fracture and Peri-Stent Contrast staining After Sirolimus-Eluting Stent Implantation on Target Lesion Revascularization

Stent Design and Comprehensive Data Review: Orsiro Cobalt Chromium Sirolimus-Eluting Stents

Very Thin-Strut Biodegradable Polymer Everolimus-Eluting And Sirolimus-Eluting Stents Shown To Be Non-Inferior To Durable Polymer Zotarolimus-Eluting Stents In All-Comers With Coronary Artery Disease

DES With Biodegradable Polymers Stand Up Well Against Durable-Polymer Stents in the Short Term

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

A Tight Spot: Drug-Eluting Stents Seem to Top Other Options for Small-Vessel Disease

STENTYS Announces CE Marking of its longest Xposition stent

Según un Meta Análisis en Red el Riesgo de Trombosis del Andamiaje con el BVS Absorb es Mayor que con Otros Stents

Higher Scaffold Thrombosis Risk With Absorb BVS vs a Wide Range of Stents: Network Meta-Analysis

iVascular completes recruitment of patients for its ANCHOR clinical trial of the sirolimus eluting stent ANGIOLITE

Micell Technologies Completes Enrollment in OCT Study Designed to Evaluate Superior Performance of MiStent SES Compared to Xience

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content